Bortezomib inhibits osteoclast activity in patients with multiple myeloma

Clinical Lymphoma and Myeloma

Volumn 7, Issue 9, 2007, Pages 587-589

  Uy, Geoffrey L ^a   Trivedi, Rachna ^a   Peles, Shachar ^a   Fisher, Nicholas M ^a   Zhang, Qin ^a   Tomasson, Michael H ^a   DiPersio, John F ^a   Vij, Ravi ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone turnover; N telopeptide; Nuclear factor B; Osteoblasts; Proteasomes

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; COLLAGEN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELPHALAN;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; AUTOTRANSPLANTATION; BONE METABOLISM; BONE TURNOVER; CELL ACTIVITY; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG MEGADOSE; FEMALE; HUMAN; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OSTEOCLAST; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; URINARY EXCRETION;

EID: 37849030704     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2007.n.045     Document Type: Article

References (11)

1. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61:3071-6.
2. Yaccoby S, Wezeman MJ, Henderson A, et al. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res 2004; 64:2016-23.
3. Zangari M, Esseltine D, Lee CK, et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 2005; 131:71-3.
4. Shimazaki C, Uchida R, Nalcano S, et al. High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation. Leukemia 2005; 19:1102-3.
5. Woitge HW, Pecherstorfer M, Li Y, et al. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary makes. J Bone Miner Res 1999; 14:792-801.
6. Franzoso G, Carlson L, Xing L, et al. Requirement for NF-kappa B in osteoclast and B-cell development. Genes Dev 1997; 11:3482-96.
7. Jimi E, Aoki K, Saito H, et al. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 2004; 10:617-24.
8. Breitkreutz I, Vallet S, Raab MS, et al. Lenalidomide and bortezomib inhibit osteoclast differentiation and activation in multiple myeloma: clinical implications. Blood 2006; 108:993a (Abstract #3485).
9. Terpos E, Heath DJ, Rahemtulla A, et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 2006; 135:688-92.
10. Chesnut CH, Bell NH, Clark GS, et al. Hormone replacement therapy in postmenopausal women: utinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997; 102:29-37.
11. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23:4925-35.